Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06723795 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Assessment and Treatment During COPD Exacerbation to Improve Diagnosis and Outcomes

Study acronym: CATCH
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Mar 1, 2027 to Jul 25, 2026
    • Study completion moved earlier from Aug 1, 2027 to Mar 1, 2027
    • Study description expanded, about 10 words
    v7
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  3. Publications: details revised at 4 of 4 entries
    • Study title expanded, about 2 words
    v5
  4. Collaborators expanded, about 1 wordv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Feb 1, 2027 to Mar 1, 2027
    • Start date changed from estimate of Feb 1, 2025 to Mar 1, 2025
    • Site details revised
    v3
  6. Secondary endpoints: 6 to 7
    • Study description expanded, about 2 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a research study involving patients hospitalized for COPD flare-ups. Patients will be assigned using a non-randomized, sequential allocation strategy (a control cohort followed by an intervention cohort) to two groups: one group will only see a pulmonologist (lung doctor), and the other group will also be seen by a cardiologist (heart doctor) during their hospital stay. Both groups will fill out a questionnaire, and the pulmonologist will review their lung disease, adjust their treatment, and recommend follow-up care. The cardiologist will also assess the second group for heart diseases (like high cholesterol, diabetes, heart disease, high blood pressure, or heart failure) and start or adjust heart treatment if needed. Both groups will be followed up by phone 1, 3, 6 and 12 months later to check for changes in treatment, new heart problems, COPD flare-ups, or death.
Trial Details
NCT Number NCT06723795
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: AstraZeneca
Conditions
(from sponsor)		 COPD (Chronic Obstructive Pulmonary Disease), Cardiovascular Diseases
Related terms Cardiovascular Diseases, Disease, Pulmonary Disease, Chronic Obstructive
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov